


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1 (Currently amended). A pharmaceutical composition for inhaled use in the respiratory tract of a mammal, comprising a compound according to Formula (I) hereinbelow:



wherein

~~R1 is selected from the group consisting of straight or branched chain lower alkyl group having from 1 to 6 carbon atoms;~~

R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl groups (having from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), ~~cycloalkyl-alkyl (having 6 to 10 carbon atoms),~~ 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms, and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X⁻ represents an anion associated with the positive charge of the N atom; and a pharmaceutically acceptable carrier or diluent suitable for oral or nasal inhalation.

2 (currently amended). A pharmaceutical composition ~~compound~~ according to claim 1 wherein the orientation of the alkyl chain attached to the tropane ring is endo.

3 (currently amended). A pharmaceutical composition ~~compound~~ according to claim 2 wherein the compound of Formula (I) is selected from the group consisting of:

(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;
and

(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-
methylbenzenesulfonate ÷ _

4 (currently amended). A pharmaceutical composition ~~compound~~ according to
claim 1 wherein X⁻ is selected from the group consisting of chloride, bromide, iodide,
sulfate, benzene sulfonate and toluene sulfonate.

5. (Cancelled)

6. (currently amended) A method of inhibiting the binding of
acetylcholine to a acetylcholine receptor in a mammal in need thereof, which comprises
contacting the acetylcholine receptor with an effective ~~its receptors in a mammal in~~
~~need thereof comprising administering a safe and effective amount of a compound~~
composition according to claim 1, and wherein the method of contacting the receptor
with the composition is via inhalation by the mouth or nose of the mammal.

7. (currently amended) A method of ~~treating a~~ inhibiting the binding of
acetylcholine to a M₃ muscarinic acetylcholine receptor ~~mediated disease, in the~~
respiratory tract of a mammal in need thereof, which comprises contacting the ~~wherein~~
M₃ muscarinic acetylcholine binds to said receptor, comprising administering a safe
~~and~~ with an effective amount of a compound composition according to claim 1 and
wherein the method of contacting the receptor with the composition is via inhalation by
the mouth or nose of the mammal.

8. (currently amended) A method according to claim 7 wherein the ~~disease is~~
~~selected from the group consisting~~ binding of the M₃ muscarinic acetylcholine receptor
is useful in the treatment of chronic obstructive lung disease, chronic bronchitis,
asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema
~~and~~ or allergic rhinitis.

9. (currently amended) A method according to claim 7 wherein administration is
via inhalation via the mouth ~~or nose~~.

10. (original) A method according to claim 7 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.

11. (currently amended) A method according to claim 7 wherein the composition ~~compound is administered to a human and~~ has a duration of action of 12 hours or more ~~for a dose of up to 1 mg~~ and the mammal is a human.

12. (currently amended) A method according to claim 11 wherein the composition ~~compound~~ has a duration of action of 24 hours or more.

13. (currently amended) A method according to claim 12 wherein the composition ~~compound~~ has a duration of action of 36 hours or more.

14. (new) A method according to claim 7 wherein administration is via inhalation via the nose.

15. (new) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth or nose, an effective amount of a composition according to Claim 1.